

In the Specification:

On page 1, in the title, please insert --Antibodies to-- before "Cell Cycle Regulatory";
please delete all text in the section entitled **Related Applications** and insert
therefor:

D1 This application is a continuation of application number 08 /893,274 , filed on July 15, 1997, now U.S. Patent No. 5,968,821, which is a continuation of 08/306,511 filed 9/14/94, now U.S. Patent No. 5,962,316; which is a continuation-in-part of 08/248,812 filed 5/25/94, now U.S. Patent No. 5,889,169; which is a continuation-in-part of 08/227,371 filed 04/14/94; which is a continuation-in-part of 08/154,915 filed 11/18/93; which claims priority to PCT/US93/09945, filed 10/18/93, and is a continuation-in-part of 07/991,997 filed 12/17/92 (abandoned); which is a continuation-in-part of 07/963,308 filed 10/16/92.**

D2 On page 4, line 33, after the term "Arg-Xaa-Ala-Xaa-Gly" insert --(SEQ ID No. 11)--; on page 5, line 7, after the term "Ser-Asp-Ile-Pro-Asp;" insert --(SEQ ID No. 12)--;

line 17, after the term "Xaa-Ala-Xaa-Gly-Asp," insert --(SEQ ID No. 13)--;

line 26, after the term "Ser-Gln-Glu-Gln-Ser.", insert --(SEQ ID No. 14)--;

on page 9, line 6, after the term "(T/K)-V(F/Y)KARD", insert --(SEQ ID No. 15)--;

line 7, after the term "(F/Y)KARD", insert --(SEQ ID No. 16)--;

line 8, after the term "KARD", insert --(SEQ ID No. 17)--;

line 31, after the term "p16 cDNA", insert --(SEQ ID No. 18)--;

line 32, after the term "exon 1.", insert --(p16ex1 (SEQ ID No. 19),

p16ex13 (SEQ ID No. 20), p16nt2 (SEQ ID No. 21), p16nt3 (SEQ

ID No. 22))**

line 33, after the term "exon 2.", insert --(p16int (SEQ ID No. 23),

p16ex15 (SEQ ID No. 24), p16ex2 (SEQ ID No. 25), p16ex14

(SEQ ID No. 26))**

D3 on page 10, line 2, after the term "exon 3.", insert --(p16EX5 (SEQ ID No. 27),
p16EX9 (SEQ ID No. 28), p16EX4 (SEQ ID No. 29), p16EX6
(SEQ ID No. 30), p16EX6A (SEQ ID No. 31))**

line 8, after the term "p16", insert --(SEQ ID No. 32)--
line 8, after the term "p15", insert --(SEQ ID No. 33)--
line 8, after the term "p13.5", insert --(SEQ ID No. 34)--
line 23, delete "uncouples" and insert therefor --uncoupled--;
on page 24, line 20, delete "pBlueBac" and insert therefor --pBLUEBAC--;
on page 28, line 38, after the term "Xaa(23)-Ala-Xaa(24)-Gly", insert --(SEQ ID No. 11)--;
on page 59, line 3, delete "pBluescript" and insert therefor --pBLUESCRIPT--;
line 7, delete "Fujix" and insert therefor --FUJIX--;
line 31, delete "propidiem" and insert therefor --propidium--; and
line 33, delete "Axiphot" and insert therefor --AXIOPHOT--.

Please replace pages 65-74 with the amended sequence listing on the replacement
enclosed herewith (pages 65-87), and renumber the claims and abstract accordingly.

In the Claims:

For the convenience of the Examiner, all claims whether or not amended are presented
below for reconsideration.

11. (Amended) An antibody preparation specifically reactive with an epitope of [the immunogen
of claim 10] an immunogen comprising a substantially pure preparation of a cell regulatory
(CCR) protein or a fragment thereof which specifically binds to a cyclin dependent kinase
(CDK), the full length form of said CCR-protein having an approximate molecular weight in the
range of 14.5kD to 16kD, in an immunogenic preparation, said immunogen being capable of
eliciting an immune response specific for said CCR-protein

58. (Reiterated) An isolated antibody, or fragment thereof, specifically immunoreactive with a
cell cycle regulatory (CCR) protein, wherein said protein comprises at least four ankyrin-repeats
and specifically binds to a cyclin-dependant kinase.